2b7a: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
Line 1: Line 1:
[[Image:2b7a.gif|left|200px]]
{{Seed}}
[[Image:2b7a.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2b7a|  PDB=2b7a  |  SCENE=  }}  
{{STRUCTURE_2b7a|  PDB=2b7a  |  SCENE=  }}  


'''The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor'''
===The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor===




==Overview==
<!--
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important intracellular mediator of cytokine signaling. Mutations of the JAK2 gene are associated with hematologic cancers, and aberrant JAK activity is also associated with a number of immune diseases, including rheumatoid arthritis. Accordingly, the development of JAK2-specific inhibitors has tremendous clinical relevance. Critical to the function of JAK2 is its PTK domain. We report the 2.0 A crystal structure of the active conformation of the JAK2 PTK domain in complex with a high-affinity, pan-JAK inhibitor that appears to bind via an induced fit mechanism. This inhibitor, the tetracyclic pyridone 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-1 , was buried deep within a constricted ATP-binding site, in which extensive interactions, including residues that are unique to JAK2 and the JAK family, are made with the inhibitor. We present a structural basis of high-affinity JAK-specific inhibition that will undoubtedly provide an invaluable tool for the further design of novel, potent, and specific therapeutics against the JAK family.
The line below this paragraph, {{ABSTRACT_PUBMED_16174768}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 16174768 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_16174768}}


==Disease==
==Disease==
Line 38: Line 42:
[[Category: Wilks, A F.]]
[[Category: Wilks, A F.]]
[[Category: Kinase]]
[[Category: Kinase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 19:56:32 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 17:18:17 2008''

Revision as of 14:18, 28 July 2008

File:2b7a.png

Template:STRUCTURE 2b7a

The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

Template:ABSTRACT PUBMED 16174768

Disease

Known disease associated with this structure: Leukemia, acute myelogenous OMIM:[147796], Myelofibrosis, idiopathic OMIM:[147796], Myeloproliferative disorder with erythrocytosis OMIM:[147796], Polycythemia vera OMIM:[147796], Thrombocythemia, essential OMIM:[147796], Budd-Chiari syndrome OMIM:[147796]

About this Structure

2B7A is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor., Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, Rossjohn J, Blood. 2006 Jan 1;107(1):176-83. Epub 2005 Sep 20. PMID:16174768

Page seeded by OCA on Mon Jul 28 17:18:17 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2b7a&oldid=708840"